Skip to Main content Skip to Navigation
Journal articles

Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn’s Disease

Abstract : Tumour necrosis factor-α [TNF-α] inhibitors have revolutionised the management of chronic inflammatory conditions. A number of cutaneous adverse events have been reported with TNF inhibition, including vasculitis. Most reactions are mild and rarely warrant treatment withdrawal. Here we describe a patient with Crohn's disease treated with adalimumab in whom severe multivisceral Henoch-Schönlein purpura developed, including neurological involvement, requiring definitive TNF blocker withdrawal.
Complete list of metadata

https://hal.univ-reims.fr/hal-03434390
Contributor : Arnaud Pommier Connect in order to contact the contributor
Submitted on : Friday, November 19, 2021 - 3:13:57 PM
Last modification on : Saturday, November 20, 2021 - 3:18:21 AM

Identifiers

Collections

Citation

Morgane Condamina, Emmanuelle Diaz, Céline Jamart, Jeffrey Loget, Anne Durlach, et al.. Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn’s Disease. Journal of Crohn's and Colitis, Elsevier - Oxford University Press, 2019, 14 (4), pp.538 - 542. ⟨10.1093/ecco-jcc/jjz164⟩. ⟨hal-03434390⟩

Share

Metrics

Record views

9